Going beyond HRR mutations: A deep-learning approach on HRD detection in ovarian cancer

Homologous recombination deficiency (HRD) is an important prognostic and predictive biomarker in ovarian cancer. It is assessed by combining information from homologous recombination repair (HRR) gene mutations, the “cause” of HRD, with a measure of genomic scarring, the “effect” of HRD. However, implementing HRD analysis in-house can be challenging due to technical limitations, such as the requirement for deep genomic profiling data. Deep learning-based approaches that leverage low-pass whole genome sequencing (WGS) can help overcome limitations and maximize insights from raw NGS data for accurate in-house HRD detection.

In this webinar, Dr. Nicola Normanno (Director, Translational Research, National Cancer Institute, Italy Pascale Foundation) presents analytical performance results from an in-house evaluation of HRD status in ovarian cancer samples using the deep learning-based SOPHiA DDM™ HRD Solution.

SOPHiA DDM™ HRD Solution is for research use only, not for use in diagnostic procedures.

Learn more about SOPHiA GENETICS technologies:
SOPHiA DDM™ HRD Solution

Sign Up To View The Webinar

First Name

Last Name

Institution

Job Title

Area of Interest

Phone

Country

State

Province

Primary Focus I am interested in somatic solutionsI am interested in germline solutions

Comments

Privacy Policy I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. View our Privacy Policy for more information.

Pardot Opt-in I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

Comments